Evidence map›Paper›PMID 39044555›Full record

ArticleHead & neck2024

Outcomes of SMARCB1-deficient sinonasal carcinoma: Largest single-center cross-sectional study.

Robbie Woods, Daniel Scholfield, Lucas Axiotakis, Conall Fitzgerald, Dauren Adilbay, Jennifer Cracchiolo, Snehal Patel, Jatin Shah, Lara Dunn, David Pfister and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical, genetic and immunohistochemical characterization of sinonasal tumors with neuroectodermal differentiation.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Robbie WoodsHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-1698-9610
Daniel ScholfieldHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-7784-1244
Lucas AxiotakisHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Conall FitzgeraldHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Dauren AdilbayHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-5555-2019
Jennifer CracchioloHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0003-4496-906X
Snehal PatelHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jatin ShahHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-6444-6592
Lara DunnDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-5318-2571
David PfisterDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Nancy LeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Snjezana DoganDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ian GanlyHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-7636-5426
Marc CohenHead and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundWe evaluate outcomes of SMARCB1-deficient sinonasal carcinomas in the largest single-institution study.

methodsRetrospective cross-sectional study of patients with SMARCB1-deficient sinonasal carcinoma between 1998 and 2024. Disease-specific survival (DSS) and recurrence-free probability (RFP) at 1 and 5 years were measured by Kaplan-Meier method.

resultsThere were 47 patients with a median age of 53. Initial pathological diagnosis was altered in 33%. Twelve (34%) patients received neoadjuvant chemotherapy, with one partial response. Curative surgical approach was undertaken in 73%. Definitive chemoradiation was administered in 20%. DSS at 1 and 5 years was 93% and 45%, respectively. RFP at 1 and 5 years was 73% and 33%, respectively. On multivariate analysis, cranial nerve involvement (p = 0.01 for DSS) remained significantly worse for DSS and overall survival.

conclusionsSMARCB1-deficient tumors had limited response to neoadjuvant chemotherapy. Cranial nerve involvement was associated with worse prognosis. Optimal treatment is unclear. Surgery should be offered to patients with resectable disease.

Indexed as

Paranasal Sinus NeoplasmsSMARCB1 ProteinAdultAgedCarcinomaCross-Sectional StudiesDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoadjuvant TherapyPrognosisRetrospective StudiesTreatment OutcomeSMARCB1 ProteinSMARCB1 protein, humaninduction chemotherapyINI‐1sinonasal carcinomaskull baseSMARCB‐1

Identifiers

PMID39044555
PMCPMC12404152

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.